5-octadecyloxy-2-furoic acid | 54857-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-octadecyloxy-2-furoic acid
• 英文别名: 5-octadecoxyfuran-2-carboxylic acid
• CAS: 54857-92-0
• 化学式: C₂₃H₄₀O₄
• 分子量: 380.568
• InChiKey: JWBRIJHICYHTCC-UHFFFAOYSA-N

物化性质

• 熔点：
  117-118 °C (decomp)
• 沸点：
  492.3±25.0 °C(Predicted)
• 密度：
  0.977±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  27
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  糠酸（呋喃甲酸） 在 溴 、 sodium hydride 作用下， 以 四氯化碳 为溶剂， 反应 25.0h， 生成 5-octadecyloxy-2-furoic acid
  参考文献：
  名称：

  烷氧基糠酸的固态分解。

  摘要：

  合成了一系列烷基长度为n = 8-18的烷氧基糠酸，并进行了固相分解研究。遵循Bawn动力学，并建立了固，液分解速率常数。他们很好地遵循了阿伦尼乌斯（Arrhenius）关系，激活能量和指数前因子是链长的函数。在n = 14和n = 16之间，这种相关性有所突破。液化点与逆温度具有预期的相关性。等动力学温度（Ti）在其他化合物系列所证明的线上下降得相当好。

  DOI：

  10.1002/jps.2600701002

文献信息

• Hypolipidemic agents RO- or RS- substituted furoic acids, esters and
  申请人：Richardson-Merrell Inc.

  公开号：US04110351A1

  公开（公告）日：1978-08-29

  Substituted furoic acids and esters and pharmaceutically acceptable salts thereof of the following general structure are useful as hypolipidemic agents: ##STR1## wherein Y represents oxygen or divalent sulfur; R represents a straight or branched alkyl chain containing from 10 to 20 carbon atoms and may be saturated or may be unsaturated containing from 1 to 4 double bonds; R.sup.1 represents hydrogen, straight or branched lower alkyl of from 1 to 6 carbon atoms, benzyl, phenethyl, pyridylmethyl, alkane-poly-yl containing from 3 to 6 carbon atoms, 1,2,3,4,5,6-cyclohexanehexayl, or Z; Z represents (A) the group ##STR2## wherein n is an integer of 2 or 3; R.sup.2 represents straight or branched lower alkyl of from 1 to 4 carbon atoms, or acyl; R.sup.3 represents hydrogen or straight or branched lower alkyl of from 1 to 4 carbon atoms with the proviso that when R.sup.3 is hydrogen, R.sup.2 is acyl; or when R.sup.2 is other than acyl, R.sup.2 and R.sup.3 taken together with the nitrogen atom to which each is attached form a monocyclic heterocyclic group, such as pyrrolidino, piperidino, morpholino, or piperazino; or (B) the group ##STR3## WHEREIN THE SUM OF THE INTEGERS M AND P IS EQUAL TO FROM 3 TO 5; AND R.sup.4 represents straight or branched lower alkyl of from 1 to 4 carbon atoms; X is an integer of from 1 to 6 with the proviso that when R.sup.1 is alkane-poly-yl or 1,2,3,4,5,6-cyclohexanehexayl, X is equal to from 2 to 6, and when R.sup.1 is other than alkane-poly-yl or 1,2,3,4,5,6-cyclohexanehexayl, X is equal to 1.

  以下一般结构的取代呋酸和酯及其药用可接受盐可用作降脂药物：其中Y代表氧或二价硫；R代表含有从10到20个碳原子的直链或支链烷基链，可以是饱和的，也可以是不饱和的，含有从1到4个双键；R.sup.1代表氢，含有从1到6个碳原子的直链或支链较低的烷基，苄基，苯乙基，吡啶基甲基，含有从3到6个碳原子的烷基多聚物，1,2,3,4,5,6-环己烷六基，或Z；Z代表(A)组##STR2##其中n是2或3的整数；R.sup.2代表含有从1到4个碳原子的直链或支链较低的烷基，或酰基；R.sup.3代表氢或含有从1到4个碳原子的直链或支链较低的烷基，但当R.sup.3为氢时，R.sup.2为酰基；或当R.sup.2不是酰基时，R.sup.2和R.sup.3与各自连接的氮原子一起形成单环杂环基团，如吡咯啉基，哌啶基，吗啉基或哌嗪基；或(B)组##STR3##其中整数M和P的总和等于3到5；R.sup.4代表含有从1到4个碳原子的直链或支链较低的烷基；X是从1到6的整数，但当R.sup.1为烷基多聚物或1,2,3,4,5,6-环己烷六基时，X等于2到6，当R.sup.1不是烷基多聚物或1,2,3,4,5,6-环己烷六基时，X等于1。
• Hypolipidemic composition and method of use
  申请人：Richardson-Merrell Inc.

  公开号：US04146623A1

  公开（公告）日：1979-03-27

  Substituted furoic acids and esters and pharmaceutically acceptable salts thereof of the following general structure are useful as hypolipidemic agents: ##STR1## wherein Y represents oxygen or divalent sulfur; R represents a straight or branched alkyl chain containing from 10 to 20 carbon atoms and may be saturated or may be unsaturated containing from 1 to 4 double bonds; R.sup.1 represents hydrogen, straight or branched lower alkyl of from 1 to 6 carbon atoms, benzyl, phenethyl, pyridylmethyl, alkane-poly-yl containing from 3 to 6 carbon atoms, 1,2,3,4,5,6-cyclohexanehexayl, or Z; Z represents ##STR2## wherein n is an integer of 2 or 3; R.sup.2 represents straight or branched lower alkyl of from 1 to 4 carbon atoms, or acyl; R.sup.3 represents hydrogen or straight or branched lower alkyl of from 1 to 4 carbon atoms with the proviso that when R.sup.3 is hydrogen, R.sup.2 is acyl; or when R.sup.2 is other than acyl, R.sup.2 and R.sup.3 taken together with the nitrogen atom to which each is attached form a monocyclic heterocyclic group, such as pyrrolidino, piperidino, morpholino, or piperazino; or ##STR3## wherein the sum of the integers m and p is equal to from 3 to 5; and R.sup.4 represents straight or branched lower alkyl of from 1 to 4 carbon atoms; X is an integer of from 1 to 6 with the proviso that when R.sup.1 is alkane-poly-yl or 1,2,3,4,5,6-cyclohexanehexayl, X is equal to from 2 to 6, and when R.sup.1 is other than alkane-poly-yl or 1,2,3,4,5,6-cyclohexanehexayl, X is equal to 1.

  以下一般结构的取代呋喃酸、酯和其药学上可接受的盐被用作降脂药物：其中，Y代表氧或二价硫；R代表含有10至20个碳原子的直链或支链烷基链，可以是饱和的或不饱和的，含有1至4个双键；R.sup.1代表氢、1至6个碳原子的直链或支链低烷基、苄基、苯乙基、吡啶甲基、含有3至6个碳原子的烷基多聚物、1,2,3,4,5,6-环己烷己基或Z；Z代表##STR2##其中n是2或3的整数；R.sup.2代表1至4个碳原子的直链或支链低烷基或酰基；R.sup.3代表氢或1至4个碳原子的直链或支链低烷基，但当R.sup.3为氢时，R.sup.2为酰基；或当R.sup.2不为酰基时，R.sup.2和R.sup.3与它们各自连接的氮原子一起形成单环杂环基团，如吡咯烷基、哌啶基、吗啉基或哌嗪基；或##STR3##其中整数m和p的总和等于3至5；R.sup.4代表1至4个碳原子的直链或支链低烷基；X是1至6的整数，但当R.sup.1为烷基多聚物或1,2,3,4,5,6-环己烷己基时，X等于2至6，当R.sup.1不为烷基多聚物或1,2,3,4,5,6-环己烷己基时，X等于1。
• Treatment of viral infections by modulation of host cell metabolic pathways
  申请人：THE TRUSTEES OF PRINCETON UNIVERSITY

  公开号：EP2581081A2

  公开（公告）日：2013-04-17

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in "suicide" of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models.; Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了病毒感染时某些代谢物浓度和通量的变化。所涉及的代谢途径中的宿主细胞酶被选为干预目标；即恢复代谢通量以不利于病毒复制，或进一步改变代谢通量导致病毒感染细胞（而非未感染细胞）"自杀 "以限制病毒传播。虽然可以选择相关代谢途径中的任何一种酶，但这些代谢途径关键控制点上的关键酶更适合作为候选的抗病毒药物靶点。这些酶的抑制剂可用于逆转或重定向病毒感染的影响。候选药物通过体外和宿主细胞以及动物模型中的筛选试验进行抗病毒活性测试；然后用动物模型测试候选化合物在预防和治疗病毒感染方面的疗效。展示酶抑制剂的抗病毒活性。
• ANTI-VIRAL COMBINATION THERAPY
  申请人：KOYUNCU Emre

  公开号：US20150139949A1

  公开（公告）日：2015-05-21

  The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.
• TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS
  申请人：The Trustees of Princeton University

  公开号：US20160346309A1

  公开（公告）日：2016-12-01

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.